Jean Terrier: COBRRA Trial – Comparing Bleeding Risks Between DOACs
Jean Terrier, Clinical Pharmacologist and Toxicologist at University of Rhode Island, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in European Heart Journal – Cardiovascular Pharmacotherapy, adding:
“New Viewpoint in European Heart Journal – Cardiovascular Pharmacotherapy
COBRRA showed 54% less clinically relevant bleeding with apixaban vs. rivaroxaban in acute VTE. Same target, so why the difference?
We discuss:
- The acute regimen for VTE
- Treatment adherence
- PK/PD differences, as exploratory hypotheses
- What should clinicians do ?
This is an exciting time for direct oral anticoagulant and clinical pharmacology. Work remains on efficacy and long-term VTE treatment, and we look forward to the COBRRA-AF trial (COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation).
Warm thanks to my coauthors Jean-Luc Reny, Youssef Daali and Pierre Fontana.”
Title: Same target but different bleeding outcomes: insights from a randomized apixaban-rivaroxaban comparison in patients with acute venous thromboembolism
Authors: Jean-Luc Reny, Youssef Daali, Jean Terrier
Stay updated with Hemostasis Today.
-
Oct 27, 2026, 08:42Kathleen Freson: SLFN14 at the Crossroads of RNA Regulation, Platelet Biogenesis and Inherited Thrombocytopenia
-
Oct 27, 2026, 08:22Ashenafi Tazebew Amare: Transfusion medicine is no longer just about the blood bag.
-
Oct 27, 2026, 08:09Emmanuel Wobo: RSUTH Performs Its First Automated Red Cell Exchange for Sickle Cell Disease in Nigeria
-
Oct 27, 2026, 05:58Cedric Hermans: An Evening of Cinema in Support of Blood Disorder Research
-
Oct 27, 2026, 04:56Ayodeji Olayanju: Why Choose between a Transfusion and Haemoglobinopathy CPD When You Can Do Both?
-
Oct 27, 2026, 04:54Aisha Suala: When One Underfilled Tube Can Mislead the Entire Laboratory Result
-
Oct 27, 2026, 04:34Incremental Mobility and Venous Thromboembolism Risk in Hospitalized Medical Patients – JTH
-
Oct 27, 2026, 04:29Matthew Hazell: From Rare Blood to AI – Reflecting on Three Days of Innovation at AABB 2026
-
Oct 27, 2026, 04:24Khairul Missa Mohd Amin: Highlights from RANZCR ASM 2026 and Building Stronger PE Care